SCHEMBL3098478

SCHEMBL3098478

CNC(=O)c1cc(C)n(-c2ccc(S(N)(=O)=O)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.51
CA2 P00918 5/20 0.50
CA9 Q16790 6/20 0.49
PTGS2 P35354 6/20 0.49
CA1 P00915 4/20 0.49
CA12 O43570 3/20 0.49
BAZ2B Q9UIF8 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
MALT1 Q9UDY8 1/20 0.48
PTGS1 P23219 2/20 0.47
EPHX2 P34913 2/20 0.47
HDAC3 O15379 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109266 0.86 PTGS2 (0.52) CHRNA7CA2CA9PTGS2CA1
SCHEMBL3117397 0.85 PTGS2 (0.58) CHRNA7CA2CA9PTGS2CA1
SCHEMBL17054303 0.83 BAZ2B (0.57) BAZ2BSMN1; SMN2NFKB1NFKB2RELA
SCHEMBL3111574 0.83 BAZ2B (0.45) CHRNA7CA2CA9PTGS2CA1
SCHEMBL3104796 0.82 CHRNA7 (0.51) CHRNA7CA2CA9PTGS2CA1
SCHEMBL3102280 0.81 PTGS2 (0.63) CA2CA9PTGS2CA1PTGS1
SCHEMBL17055465 0.81 MALT1 (0.71) BAZ2BSMN1; SMN2NFKB1NFKB2RELA
SCHEMBL14292306 0.81 BAZ2B (0.48) BAZ2BNFKB1NFKB2RELAMALT1
SCHEMBL5698750 0.80 MALT1 (0.80) CHRNA7PTGS2SMN1; SMN2NFKB1NFKB2
SCHEMBL3101600 0.80 CA9 (0.72) CHRNA7CA2CA9PTGS2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
WO-2008017932-A2 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE PFIZER PRODUCTS INC. (US) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE CA2, CA7, CA9 CHRNA7 3165/4885CA2 1/4885CA9 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.